Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Citichem India's board approved issuing up to 47,00,000 convertible warrants at Rs. 29 per warrant, aggregating to Rs. 13.63 crore, on a preferential basis under SEBI ICDR Regulations. Each warrant is convertible into one equity share (face value Rs. 10) within 18 months from allotment. Promoters Arif Esmail Merchant (MD) and Hashim Arif Merchant will subscribe to 21.5 lakh warrants each, while non-promoter Padmakar Jagannath Murodiya will take 4 lakh warrants — meaning about 91% of the issue is promoter-funded. This supersedes an earlier approved preferential issue from the September 2025 AGM. Separately, the board approved H1 FY26 (ended Sept 30, 2025) unaudited results showing revenue from operations of Rs. 851.68 lakhs (vs Rs. 167.26 lakhs in H1 FY25) and profit after tax of Rs. 68 lakhs (vs Rs. 12.25 lakhs), reflecting strong YoY growth.
A promoter-heavy fundraise signals insider confidence and will bolster equity capital without immediate dilution, though conversion within 18 months could expand the share count by ~69% of current equity (47 lakh warrants vs 68 lakh existing share capital). The sharp jump in H1 FY26 revenue and profits is a positive operational signal for shareholders.